Vaccine Development

Vaccine Development Can be Progressed by Latest Research in T Cells Which Can Prevent Acute Viral Infections

By Editor's Desk
11 January 2025

Researchers used a cross-vaccination strategy in the trial, which involved 33 healthy adult volunteers between the ages of 21 and 45.

Clinical Trials News Research

New Vaccine Developed for Lassa Fever; ready for Phase 1 Trials

By Journal Updates
13 September 2024

A novel vaccine candidate that offers protection against Lassa fever has been developed by researchers from Thomas Jefferson University and the University of Maryland Baltimore, [Read More…]

Tag: Vaccine Development

Vaccine Development Can be Progressed by Latest Research in T Cells Which Can Prevent Acute Viral Infections

New Vaccine Developed for Lassa Fever; ready for Phase 1 Trials

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement